Rural GLP-1 chart review: 40 adults

A retrospective review of 40 adults in one rural primary care clinic found that treatment with tirzepatide or semaglutide was associated with lower A1c, body mass index, blood pressure, LDL cholesterol and triglycerides after 3 to 24 months. Every participant had an A1c in the normoglycemic range at follow-up. The study did not randomize treatment, include an untreated comparison group or report separate outcomes for the two medicines, so it cannot show that either drug caused those changes^[1].

The chart review followed routine care

Holland and colleagues examined existing records from adults with prediabetes and overweight or obesity at a single rural primary care clinic. This was a retrospective chart review, meaning the researchers looked back at care that had already happened rather than assigning treatment in advance. The 40 adults had received semaglutide or tirzepatide for periods ranging from 3 to 24 months. The primary measures were body mass index and hemoglobin A1c, a blood test that reflects average glucose over roughly three months. Secondary measures were systolic and diastolic blood pressure, LDL and HDL cholesterol, and triglycerides^[2].

That wide treatment window matters. A person observed for three months had much less time for weight and laboratory values to change than someone observed for two years. The abstract does not report how many patients received each medicine, the doses used, whether treatment changed during follow-up or how missing measurements were handled. It also does not describe concurrent diet, activity or other medicines. Those details would be needed to judge how much of the observed change can reasonably be associated with the two drugs.

A1c and several risk markers improved

The authors reported statistically significant improvements in A1c, body mass index, systolic and diastolic blood pressure, LDL cholesterol and triglycerides, with p values below .001. All 40 participants reached an A1c level in the normoglycemic range. HDL cholesterol did not change significantly^[1]. These are group-level associations drawn from clinical records. The abstract does not provide the starting and follow-up averages, absolute changes, confidence intervals or results split by drug, so the size and precision of each change cannot be reconstructed from the indexed record.

The normoglycemic A1c finding is the clearest headline, but it needs the same caution. Prediabetes is defined through glycemic measurements, and A1c can move with weight change, medicine use and other clinical factors. Without an untreated group, the review cannot estimate how many participants would have returned to normoglycemia under usual care alone. Nor can it establish whether tirzepatide and semaglutide performed differently. The paper's combined analysis answers a narrower question: what happened in this clinic among patients who received either treatment.

The design cannot establish cause

The authors explicitly describe the results as associations and warn that observational design and potential confounding limit interpretation^[2]. Treatment was not assigned at random. Clinicians may have selected a medicine according to patient history, access, response or tolerance. People who remained in care long enough to have follow-up laboratory results may also differ from those who stopped treatment or left the clinic. A chart review can capture routine practice, but it cannot balance those influences as a randomized comparison would.

The small, single-clinic sample also limits generalizability. Rural practices differ in staffing, referral access, insurance coverage and local population. Forty records can reveal a useful local pattern, yet they do not represent all rural adults with prediabetes. The abstract reports no adverse events, discontinuations or treatment costs. Their absence from the abstract must not be read as evidence that none occurred. This paper is an outcomes snapshot, not a full benefit and harm assessment.

What this adds to prediabetes evidence

Randomized trials are designed to estimate treatment effects under defined conditions. This review asks a different question about routine primary care, where follow-up length varies and clinicians work with the patients who present to them. Its contribution is the setting: adults with prediabetes treated in one rural clinic, a population the authors say has limited routine-care evidence. The findings support further study with larger samples, explicit comparison groups and drug-specific results. They do not establish that early treatment prevents type 2 diabetes or cardiovascular events.

The cardiometabolic measures are risk factors, not clinical events. Lower blood pressure or LDL may be favorable, but this review did not measure heart attacks, strokes or diabetes diagnoses as reported outcomes. It also cannot identify which part of care produced the changes. Any reading of the paper should keep the endpoint level clear: laboratory values and body mass index changed during observed treatment, while long-term disease prevention remained outside the study.

What readers should take from the result

The study offers a modest real-world signal that semaglutide or tirzepatide use in rural primary care can coincide with improved glycemic and cardiometabolic measurements. It does not provide a head-to-head comparison, a personal forecast or a treatment protocol. Decisions about prediabetes care depend on individual risk, medical history, access and possible harms, and belong with a qualified healthcare professional. The useful next result would be a larger controlled study that reports absolute changes, separates the two medicines and accounts for follow-up time and other care.